The Study
SAT469 Risk Factors for Relapse in Graves’ Disease and the Clinical Outcomes of Radioactive Iodine Treatment in Relapsed Cases
This study looked back at patients who had Graves' disease and found that those who relapsed tended to have higher levels of certain blood markers. But it doesn't prove those high levels caused the relapse—maybe other things were going on. It just shows a pattern, like noticing that kids who eat more candy also get more cavities, but candy might not be the only reason.
Analysis score
Maximum 58 for a case-control study.
Where the score came from
Some people with an overactive thyroid (Graves' disease) get better with pills, but others relapse and need radioactive iodine treatment.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 558 / 100
Quality score
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
Key takeaways
Summary
Based on the study abstract and findings.
- 1If your thyroid markers are very high, pills are unlikely to work long-term — radioactive iodine is a reliable next step that usually fixes it permanently.
- 2High antibody and hormone levels at diagnosis (TRAb ≥10.3, FT4 ≥56.7, FT3 ≥24.4) mean higher chance of relapse.
- 3After radioactive iodine, 92% become hypothyroid, and only 11% need more treatment.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Journal of the Endocrine Society
Year
2023
Authors
Li WingChing, Xiao ying Khor, F. Carter, Quinta Ashcroft, V. Chandrabalan, Pappachan Joseph
Related Content
Claims (6)
Among people with Graves' disease who receive radioactive iodine treatment, about three out of four are women, and the typical age at treatment is 48 years.
For patients with Graves' disease and high levels of TRAb, FT4, or FT3, doctors often recommend radioactive iodine ablation as the first treatment, even though no randomized trials have shown it works better than antithyroid drugs.
Patients with newly diagnosed Graves' disease who have thyroid hormone and antibody levels above specific thresholds are more likely to experience a return of the disease after completing antithyroid drug treatment.
Patients with Graves' disease treated with a fixed dose of 555 MBq of radioactive iodine develop hypothyroidism in about 92% of cases within three months, irrespective of their initial thyroid hormone levels.
About 11 out of 100 people with Graves' disease do not respond to one dose of 555 MBq radioactive iodine, but 6 out of 10 of those people respond to a second dose of radioactive iodine.
After treatment for Graves' disease, some patients permanently need thyroid hormone medication, while others regain normal thyroid function and no longer need medication.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.